Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHAT! RCT: Continuous ethinylestradiol/levonorgestrel vs vitamin E for menstrually-related and perimenopausal migraine
2024-517127-40-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Catamenial Migraine and migraine comparing Continuous Microgynon 30 with Vitamin E 400 IU (2 arms). Primary endpoint: Primary: Change in mean monthly migraine days at 12 weeks. Planned start Nov 2024; status: authorised.
02
Drugs
ethinylestradiol + levonorgestrelvitamin e
03
Conditions
Catamenial Migrainemigraine
Beyond the preview
Go deeper on 2024-517127-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517127-40-00.